Supplementary Materials for

Similar documents
Supplementary Figure 1. PD-L1 is glycosylated in cancer cells. (a) Western blot analysis of PD-L1 in breast cancer cells. (b) Western blot analysis

RAW264.7 cells stably expressing control shrna (Con) or GSK3b-specific shrna (sh-

Nature Structural & Molecular Biology: doi: /nsmb.3218

Supplementary Materials for

Supplementary Figure 1.TRIM33 binds β-catenin in the nucleus. a & b, Co-IP of endogenous TRIM33 with β-catenin in HT-29 cells (a) and HEK 293T cells

Supplementary Figure 1. Characterization of NMuMG-ErbB2 and NIC breast cancer cells expressing shrnas targeting LPP. NMuMG-ErbB2 cells (a) and NIC

Supplementary Figures

Supplementary Materials for

supplementary information

Supplemental Data. TGF-β-mediated mir-181a expression promotes breast cancer metastasis by targeting Bim.

SUPPLEMENTARY FIGURES AND TABLE

(a) Significant biological processes (upper panel) and disease biomarkers (lower panel)

Supplementary Figure 1 IMQ-Induced Mouse Model of Psoriasis. IMQ cream was

SUPPLEMENTARY FIG. S5. ROS regulated the signaling responses of A. gambiae 4a3B cells to human insulin. (A) 4a3B cells were stimulated with 6000

SUPPLEMENTARY FIGURES

Supplementary Materials for

SUPPLEMENTARY INFORMATION

Supplementary Materials

Cell Signaling part 2

Supplementary Materials for

Supplementary Materials for

Part-4. Cell cycle regulatory protein 5 (Cdk5) A novel target of ERK in Carb induced cell death

m 6 A mrna methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer

Supplementary Fig. 1. GPRC5A post-transcriptionally down-regulates EGFR expression. (a) Plot of the changes in steady state mrna levels versus

Supplementary Materials for

Supplementary Figure 1. Deletion of Smad3 prevents B16F10 melanoma invasion and metastasis in a mouse s.c. tumor model.

2.5. AMPK activity

Supplemental Figure 1. Western blot analysis indicated that MIF was detected in the fractions of

SUPPLEMENTARY INFORMATION

Supplementary Information. Induction of human pancreatic beta cell replication by inhibitors of dual specificity tyrosine regulated kinase

Loss of RhoA promotes skin tumor formation. Supplementary Figure 1. Loss of RhoA does not impair F-actin organization.

Intracellular MHC class II molecules promote TLR-triggered innate. immune responses by maintaining Btk activation

Supplemental Figures:

A Hepatocyte Growth Factor Receptor (Met) Insulin Receptor hybrid governs hepatic glucose metabolism SUPPLEMENTARY FIGURES, LEGENDS AND METHODS

Supplementary Figure 1. Normal T lymphocyte populations in Dapk -/- mice. (a) Normal thymic development in Dapk -/- mice. Thymocytes from WT and Dapk

S1a S1b S1c. S1d. S1f S1g S1h SUPPLEMENTARY FIGURE 1. - si sc Il17rd Il17ra bp. rig/s IL-17RD (ng) -100 IL-17RD

Supplementary Materials for

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY FIGURES AND TABLES

(A) RT-PCR for components of the Shh/Gli pathway in normal fetus cell (MRC-5) and a

Integrin CD11b negatively regulates TLR-triggered inflammatory responses by. activating Syk and promoting MyD88 and TRIF degradation via cbl-b

ANGPTL2 increases bone metastasis of breast cancer cells through. Tetsuro Masuda, Motoyoshi Endo, Yutaka Yamamoto, Haruki Odagiri, Tsuyoshi

Supplementary Materials for

Supplemental Table I

Supplementary Table S1. Tumor samples used for analysis Tumor size (cm) BNG (grade) ERα PR. pn-

Supplementary Materials for

PKCζ Promotes Breast Cancer Invasion by Regulating Expression of E-cadherin and Zonula Occludens-1 (ZO-1) via NFκB-p65

W/T Itgam -/- F4/80 CD115. F4/80 hi CD115 + F4/80 + CD115 +

Supplementary Figure 1. HOPX is hypermethylated in NPC. (a) Methylation levels of HOPX in Normal (n = 24) and NPC (n = 24) tissues from the

SUPPLEMENTARY INFORMATION

Cells and reagents. Synaptopodin knockdown (1) and dynamin knockdown (2)

Receptor mediated Signal Transduction

Supplementary Materials for

G-Protein Signaling. Introduction to intracellular signaling. Dr. SARRAY Sameh, Ph.D

Supplementary Fig. S1. Schematic diagram of minigenome segments.

Supplementary Figure 1

supplementary information

Supplementary Figure 1. Spatial distribution of LRP5 and β-catenin in intact cardiomyocytes. (a) and (b) Immunofluorescence staining of endogenous

HEK293FT cells were transiently transfected with reporters, N3-ICD construct and

Supplementary Figure 1: STAT3 suppresses Kras-induced lung tumorigenesis

Type of file: PDF Size of file: 0 KB Title of file for HTML: Supplementary Information Description: Supplementary Figures

4.2 RESULTS AND DISCUSSION

Supplementary Figure 1. Establishment of prostacyclin-secreting hmscs. (a) PCR showed the integration of the COX-1-10aa-PGIS transgene into the

Supplemental information

Supplementary Figure S1 Supplementary Figure S2

Supplementary Materials for. c-abl Activation Plays a Role in α-synucleinopathy Induced Neurodegeneration

SUPPLEMENTARY INFORMATION

Inhibition of TGFβ enhances chemotherapy action against triple negative breast cancer by abrogation of

Supplementary Figure 1. Procedures for p38 activity imaging in living cells. (a) Schematic model of the p38 activity reporter. The reporter consists

Soft Agar Assay. For each cell pool, 100,000 cells were resuspended in 0.35% (w/v)

Supplementary Figure 1. IHC and proliferation analysis of pten-deficient mammary tumors

Supplementary Fig. 1 eif6 +/- mice show a reduction in white adipose tissue, blood lipids and normal glycogen synthesis. The cohort of the original

Supplementary Figure 1

Department of Chemistry, Université de Montréal, C.P. 6128, Succursale centre-ville, Montréal, Québec, H3C 3J7, Canada.

SUPPLEMENTARY INFORMATION

Supplementary Figure 1. SA-β-Gal positive senescent cells in various cancer tissues. Representative frozen sections of breast, thyroid, colon and

Supplementary Materials for

Supplementary Materials for

EGFR shrna A: CCGGCGCAAGTGTAAGAAGTGCGAACTCGAGTTCGCACTTCTTACACTTGCG TTTTTG. EGFR shrna B: CCGGAGAATGTGGAATACCTAAGGCTCGAGCCTTAGGTATTCCACATTCTCTT TTTG

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY FIGURES

Supplementary Materials for

FGL2 A new biomarker for cancer in a simple blood test

Supplementary Figure 1: si-craf but not si-braf sensitizes tumor cells to radiation.

Negative Regulation of c-myc Oncogenic Activity Through the Tumor Suppressor PP2A-B56α

SUPPLEMENTARY INFORMATION

T H E J O U R N A L O F C E L L B I O L O G Y

Supplementary Materials for

p = formed with HCI-001 p = Relative # of blood vessels that formed with HCI-002 Control Bevacizumab + 17AAG Bevacizumab 17AAG

SUPPLEMENTARY INFORMATION

Supplementary Figure 1. mrna expression of chitinase and chitinase-like protein in splenic immune cells. Each splenic immune cell population was

Figure S1. Reduction in glomerular mir-146a levels correlate with progression to higher albuminuria in diabetic patients.

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Supporting Information

Nature Immunology: doi: /ni Supplementary Figure 1. IC261 inhibits a virus-induced type I interferon response.

Trim29 gene-targeting strategy. (a) Genotyping of wildtype mice (+/+), Trim29 heterozygous mice (+/ ) and homozygous mice ( / ).

Supplementary Figure 1. PAQR3 knockdown inhibits SREBP-2 processing in CHO-7 cells CHO-7 cells were transfected with control sirna or a sirna

hexahistidine tagged GRP78 devoid of the KDEL motif (GRP78-His) on SDS-PAGE. This

Supplemental Information

Supplementary Information

Transcription:

www.sciencesignaling.org/cgi/content/full/8/364/ra18/dc1 Supplementary Materials for The tyrosine phosphatase (Pez) inhibits metastasis by altering protein trafficking Leila Belle, Naveid Ali, Ana Lonic, Xiaochun Li, James L. Paltridge, Suraya Roslan, David Herrmann, James R. W. Conway, Freya K. Gehling, Andrew G. Bert, Lesley A. Crocker, Anna Tsykin, Gelareh Farshid, Gregory J. Goodall, Paul Timpson, Roger J. Daly, Yeesim Khew-Goodall* The PDF file includes: *Corresponding author. E-mail: yeesim.khew-goodall@health.sa.gov.au Published 17 February 2015, Sci. Signal. 8, ra18 (2015) DOI: 10.1126/scisignal.2005547 Fig. S1. knockdown promotes invasiveness in MDA-MB-231 cells. Fig. S2. promotes the secretion of TGFβ in human breast cancer cell lines. Fig. S3. Relative cytokine abundance in conditioned media from breast cancer cells after overexpression or knockdown. Fig. S4. Relative abundance of cytokine mrna transcripts in breast cancer cells after overexpression or knockdown. Fig. S5. Schematic of the injection protocol used to test the effect of conditioned medium on the growth and metastasis of breast cancer cells in mice. Fig. S6. Identification of substrates by differential phosphoproteomics. Fig. S7. Total protein abundance of candidate substrates is unaffected by knockdown. Fig. S8. Western blot analyses to ascertain overexpression or knockdown efficiencies. Fig. S9. Correlation between technical replicate SILAC-MS experiments. Table S1. List of candidate (Pez) substrates from SILAC-MS screen. References (53 62)

Supplementary Materials. A B 231- Invasion Proliferation 231-sh Number of invaded cells 3500 3000 2500 2000 1500 *** sh Proliferative index [%] Cells within matrix 80 60 40 20 0 sh Proliferative index [%] Cells on top of matrix 80 60 40 20 0 *** sh Figure S1: knockdown promotes invasiveness in MDA-MB-231 cells. The invasive capacity of control MDA-MB-231 cells (231-) and knockdown cells (231-sh) was assessed by 3-D organotypic collagen I invasion assays. (A) Representative images of H&E stained sections from invasion assays after 12 days of invasion. Scale bars, 100 µm. Quantification of invasion (A), and proliferation (B) as measured by Ki67 staining of cells within or on top of the matrix. Data are means ± SEM from 3 independent experiments. **p<0.01, Student s t-test.

MDA-MB-468 MDA-MB-231 TGF-beta1 (pg/ml) TGF-beta1 (pg/ml) Figure S2: promotes the secretion of TGFβ in human breast cancer cell lines. Total TGFβ1 abundance in conditioned media from 468-EV, 468- (n=3 clones each), 231- and 231- sh clones (n=4 clones each) measured using a TGFβ1 ELISA. *p<0.05, two-tailed t-test.

Figure S3: Relative cytokine abundance in conditioned media from breast cancer cells after overexpression or knockdown. Quantitation of raw data (total pixels) from chemiluminenscent detection of array membranes for cytokine content in MDA-MB-468 CM pooled from 3 clones (top panel) and MDA-MB-231 CM pooled from 4 clones (bottom panel). Each symbol represents a duplicate spot on the array.

Relative mrna 5 4 3 2 1 MDA-MB-468 p=0.02 * EV 0 6 MDA-MB-231 sh Relative mrna 4 2 p=0.009 ** p=0.01 * 0 Figure S4: Relative abundance of cytokine mrna transcripts in breast cancer cells after overexpression or knockdown. The abundance of mrna transcripts that encode cytokines displaying altered presence in conditioned medium upon overexpression or knockdown was quantified in 468-EV (n=3 clones), 468- (n=3 clones), 231-NC (n=4 clones) and 231-sh (n=4 clones) by quantitative RT-PCR, and normalized to β-actin internal control. P values were derived using a twotailed t-test.

Daily IP injections of CM for 3 days (pre-conditioning) Implant cells into MFP of both sets of mice cells Continued daily IP injections of CM for 30 days sh CM CM sh Figure S5: Schematic of the injection protocol used to test the effect of conditioned medium on the growth and metastasis of breast cancer cells in mice. MFP, mammary fat pads; IP, intraperitoneal; CM, conditioned medium;, control shrna-transfected cell cultures; sh, - targeted shrna-transfected cell cultures.

A actin B sh cells cells Figure S6. Identification of substrates by differential phosphoproteomics. (A) Representative Western blotting analysis for and Actin in MDA-MB-231 cells stably expressing a shrna (sh) or non-targeting shrna (). (B) Workflow for SILAC-MS phosphoproteomics to identify proteins that are differentially tyrosine phosphorylated when is reduced.

INPPL1 IRS1 actin RIN1 EEF1A1 actin TYK2 actin Figure S7: Total protein abundance of candidate substrates is unaffected by knockdown. Representative Western blotting analysis of 231- and 231-sh cell lysates for a selection of candidate substrates identified in the SILAC-MS screen.

A RIN1 actin GFP IRS1 B RIN1 PRKCD C D RIN1 RIN1 Figure S8: Western blot analyses to ascertain overexpression or knockdown efficiencies. (A) Western blotting in lysates from MDA-MB-468 cells transfected with the indicated plasmids. Unlabeled lane is an irrelevant sample. (B) Western blot analysis of lysates from primary human lymphatic endothelial cells transfected with the indicated sirnas. (C and D) Western blotting analysis of lysates from transfected BT549 cells. Blots are representative of 3 experiments.

Experiment 1 sh(h):(l) Technical Replicates A/B Experiment 2 sh(l):(h) (Inverse) Technical Replicates A/B A A B A B B SILAC Ratio (B) SILAC Ratio (B) PY100 IP SILAC Ratio SILAC Ratio (A) C A B A B D SILAC Ratio (B) SILAC Ratio (B) PY20 IP SILAC Ratio SILAC Ratio (A) E SILAC Ratios (Exp 2) SILAC Ratios (Exp

Figure S9. Correlation between technical replicate SILAC-MS experiments. Venn diagrams indicating degree of overlap for high confidence phospho-peptides from technical replicates from Experiments 1 and 2 for py100 (A) and py20 IPs (C). Correlation coefficients (R2) for phosphotyrosine peptide SILAC ratios from technical replicates from Experiments 1 and 2 for py100 (B) and py20 IPs (D). (E) Correlation between biological replicate SILAC-MS experiments for peptides displaying at least +/-1.2- fold change in both experiments. The correlation coefficient (R2) and p values were obtained by linear regression analysis (GraphPad Prism).

Candidate UniProt Modified Fold change Name Substrate ID site Exp 1 Exp 2 Role of phosphorylation at identified tyrosine residue >1.2-fold (Exp 1&2) MK01 P28482 Mitogen-activated protein kinase 1 (ERK2) Tyr 187 1.4 3.6 Activation of kinase activity 53 DYRK1A Q13627 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Tyr 145 1.9 1.4 Non-nuclear localisation 54 RIN1 Q13671 Ras and Rab interactor 1 Tyr 36 1.7 1.7 Abl kinase activation / EGFR stabilisation 55 MK03 P27361 Mitogen-activated protein kinase 3 (ERK1) Tyr 204 1.6 1.4 Activation of kinase activity 53 EF1A1 P68104 Elongation factor 1-alpha 1 Tyr 141 1.5 1.5 Unknown P85B O00459 Phosphatidylinositol 3-kinase regulatory subunit beta Tyr 464 1.5 1.2 Unknown PRP4B Q13523 Serine/threonine-protein kinase PRP4 homolog Tyr 849 1.3 1.4 Unknown >1.2-fold (Exp 1) KPCD Q05655 Protein kinase C delta type Tyr 374 1.4 <1.2 Unknown ACK1 Q07912 Activated CDC42 kinase 1 Tyr 596 1.3 <1.2 Associated with clathrin-coated pit formation 56 CALM P62158 Calmodulin Tyr 100 1.3 <1.2 Enhanced interaction with binding partners 57 SHB Q15464 SH2 domain-containing adapter protein B Tyr 268 1.3 <1.2 Unknown SHB Q15464 SH2 domain-containing adapter protein B Tyr 336 1.3 <1.2 Unknown TYK2 P29597 Non-receptor tyrosine-protein kinase TYK2 Tyr 292 1.3 <1.2 Unknown DYRK1A Q13627 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Tyr 321 1.2 <1.2 Activation of kinase activity 58

GSK3A P49840 Glycogen synthase kinase-3 alpha Tyr 279 1.2 <1.2 Activation of kinase activity 59 >1.2-fold (Exp 2) SHIP2 O15357 Phosphatidylinositol-3,4,5-trisphosphate 5-phosphatase 2 Tyr 986 <1.2 1.8 Activation of phosphatase activity / ubiquitination 60,61 IRS1 P35568 Insulin receptor substrate 1 Tyr 662 <1.2 1.3 Interaction with p85 subunit of PI3K 62 Table S1: List of candidate (Pez) substrates from the SILAC-MS screen. List of proteins and tyrosine residues for which an increase in tyrosine phosphorylation was detected in cells hypomorphic for Pez in one or both replicate experiments, implicating them as candidate Pez substrates. Reported roles for tyrosine phosphorylation at these specific residues are also indicated.